Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib (NCT05280509)
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With Ruxolitinib in Janus-associated Kinase Inhibitor (JAKi) Treatment-Naïve Myelofibrosis (MF) Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
🩺 Plain-English Summary (8th-Grade Level)
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or Post ET MF) who are JAKi treatment-naïve or those who have a suboptimal response to ruxolitinib.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- University of Alabama at Birmingham — Birmingham, Alabama
- Gabrail Cancer Center — Canton, Ohio
- University of Cincinnati (UC) — Cincinnati, Ohio
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- CHU Angers — Angers,
- AP-HM - Hôpital de la Timone — Marseille,
- CHU de Nice - Hopital L'Archet II — Nice,
- Hôpital Saint Louis - AP-HP — Paris,
- Centre Hospitalier Lyon Sud — Pierre-Bénite,
- Marien Hospital Duesseldorf — Düsseldorf,
- Klinik fur Innere Medizin IV - Hamatologie/Onkologie, Universitatsklinikum Hall — Halle,
- IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola — Bologna,
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano — Milan,
- Azienda Ospedaliera di Perugia-Ospedale S. Maria della Misericordia — Perugia,
- Pratia Onkologia Katowice — Katowice,
- Hospital Universitari Arnau de Vilanova — Lleida,
- Hospital Universitario Ramon y Cajal — Madrid,
- Hospital Universitario Virgen de la Victoria — Málaga,
- Hospital Quironsalud de Zaragoza — Zaragoza,
📞 Contact the Study Coordinator
Phone: (650) 542-0136
Email: jmei@teliospharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Myelofibrosis
- Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms — Birmingham, Alabama
- Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis — Calgary, Alberta
- Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis — Birmingham, Alabama
- Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) — Birmingham, Alabama
- A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis — Pasadena, California
- A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) — Newport Beach, California
Explore by condition: All Myelofibrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.